DIVERSIFIED HEALTHCARE TRUST
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Notes to Consolidated Financial Statements F-
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(dollar amounts in thousands, except per share data or as otherwise stated)
Note 1. Business
Diversified Healthcare Trust is a real estate investment trust, or REIT, organized under Maryland law, which owns medical office and life science properties, senior living communities and other healthcare related properties throughout the United States. As of December 31, 2024, we owned 367 properties located in 36 states and Washington, D.C.
As of December 31, 2024, our owned properties include:98 medical office and life science properties with approximately 8.0 million rentable square feet;259 senior living communities, including independent living (including active adult), assisted living, memory care and skilled nursing facilities, or SNFs, with approximately 27,000 living units; and 10 wellness centers with approximately 812,000 square feet of interior space plus outdoor developed facilities.
As of December 31, 2024, we also owned an equity interest in each oftwo unconsolidated joint ventures that own medical office and life science properties located infive states with an aggregate of approximately 2.2 million rentable square feet.
Note 2. Summary of Significant Accounting Policies
BASIS OF PRESENTATION. Our consolidated financial statements include the accounts of Diversified Healthcare Trust, we, us or our, and our subsidiaries, all of which are 100% owned directly or indirectly by us as of December 31, 2024. All intercompany transactions and balances with or among our consolidated subsidiaries have been eliminated.
REAL ESTATE PROPERTIES. We record properties at our cost and calculate depreciation on real estate investments on a straight line basis over estimated useful lives generally up to 40 years.
We allocate the purchase prices of our properties to land, building and improvements based on determinations of the fair values of these assets assuming the properties are vacant. We determine the fair value of each property using methods similar to those used by independent appraisers, which may involve estimated cash flows that are based on a number of factors, including capitalization rates and discount rates, among others. In some circumstances, we engage independent real estate appraisal firms to provide market information and evaluations which are relevant to our purchase price allocations and determinations of depreciable useful lives; however, we are ultimately responsible for the purchase price allocations and determinations of useful lives. We allocate a portion of the purchase price to above market and below market leases based on the present value (using an interest rate which reflects the risks associated with acquired in place leases at the time each property was acquired by us) of the difference, if any, between (i) the contractual amounts to be paid pursuant to the acquired in place leases and (ii) our estimates of fair market lease rates for the corresponding leases, measured over a period equal to the terms of the respective leases. The terms of below market leases that include bargain renewal options, if any, are further adjusted if we determine that renewal is probable. We allocate a portion of the purchase price to acquired in place leases and tenant relationships based upon market estimates to lease up the property based on the leases in place at the time of purchase. In making these allocations, we consider factors such as estimated carrying costs during the expected lease up periods, including real estate taxes, insurance and other operating income and expenses and costs, such as leasing commissions, legal and other related expenses, to execute similar leases in current market conditions at the time a property was acquired by us. We allocate this aggregate value between acquired in place lease values and tenant relationships based on our evaluation of the specific characteristics of each tenant's lease. However, we have not separated the value of tenant relationships from the value of acquired in place leases because such value and related amortization expense is immaterial to our consolidated financial statements. If the value of tenant relationships becomes material in the future, we may separately allocate those amounts and amortize the allocated amount over the estimated life of the relationships.
We amortize capitalized above market lease values (included in acquired real estate leases and other intangible assets, net in our consolidated balance sheets) as a reduction to rental income over the remaining non-cancelable terms of the respective leases. We amortize capitalized below market lease values (included in other liabilities in our consolidated balance sheets) as an increase to rental income over the non-cancelable periods of the respective leases. We amortize the value of in place leases exclusive of the value of above market and below market in place leases to depreciation and amortization expense over the remaining non-cancelable periods of the respective leases and during the years ended December 31, 2024, 2023 and 2022, such amortization totaled $7,367, $10,996 and $11,524, respectively. If a lease is terminated prior to its stated expiration, we fully amortize the unamortized amount relating to that lease at that time.
As of December 31, 2024 and 2023, our acquired real estate leases and assumed real estate lease obligations, excluding properties held for sale, if any, were as follows:
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Acquired real estate leases: | ||
| Capitalized above market lease values | $2,846 | $3,804 |
| Less: accumulated amortization | (2,324) | (3,001) |
| Capitalized above market lease values, net | 522 | 803 |
| Lease origination value | 66,731 | 88,569 |
| Less: accumulated amortization | (40,953) | (55,424) |
| Lease origination value, net | 25,778 | 33,145 |
| Acquired real estate leases and other intangible assets, net | $26,300 | $33,948 |
| Assumed real estate lease obligations: | ||
| Capitalized below market lease values | $1,600 | $2,340 |
| Less: accumulated amortization | (1,305) | (1,872) |
| Assumed real estate lease obligations, net | $295 | $468 |
As of December 31, 2024, the weighted average amortization periods for capitalized above market lease values, lease origination value and capitalized below market lease values were 4.9 years,7.2 years and 3.3 years, respectively. Future amortization of net acquired real estate lease assets and obligations to be recognized over the current terms of the associated leases as of December 31, 2024 is estimated to be $5,008 in 2025, $4,410 in 2026, $3,532 in 2027, $2,578 in 2028, $2,422 in 2029 and $8,055 thereafter.
CASH AND CASH EQUIVALENTS. We consider highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.
RESTRICTED CASH. Restricted cash consists of amounts escrowed for real estate taxes, insurance and capital expenditures at certain of our mortgaged properties. Prior to our repayment in full of the $450,000 outstanding under our then secured credit facility and termination of our credit agreement in December 2023, restricted cash also consisted of amounts held as collateral pursuant to our credit agreement.
EQUITY METHOD INVESTMENTS. As of December 31, 2024, we owned a 10% equity interest in an unconsolidated joint venture that owns a life science property located in Boston, Massachusetts, or the Seaport JV, and a 20% equity interest in an unconsolidated joint venture for 10 medical office and life science properties, or the LSMD JV. The properties owned by the Seaport JV and LSMD JV are encumbered by an aggregate $620,000 and $456,625 of mortgage debts, respectively. We do not control the activities that are most significant to these joint ventures and, as a result, we account for our investment in these joint ventures under the equity method of accounting under the fair value option. See Notes 3 and 10 for more information regarding these joint ventures.
As of December 31, 2024, we owned approximately 34.0% of the outstanding common shares of AlerisLife Inc., or AlerisLife. We do not control the activities that are most significant to AlerisLife and, as a result, we account for our non-controlling interest in AlerisLife using the equity method of accounting. See Notes 3 and 8 for more information regarding our investment in AlerisLife.
DEBT ISSUANCE COSTS. Debt issuance costs include issuance or assumption costs related to borrowings and we amortize those costs as interest expense over the terms of the respective loans. Debt issuance costs for our senior secured and unsecured notes and other secured debt totaled $68,067 and $67,475 at December 31, 2024 and 2023, respectively, and accumulated amortization of debt issuance costs totaled $32,307 and $22,065, respectively, and are presented in our consolidated balance sheet as a direct deduction from the associated debt liability. Future amortization of debt issuance costs to be recognized with respect to our loans as of December 31, 2024 is estimated to be $14,886 in 2025, $2,741 in 2026, $2,247 in 2027, $1,871 in 2028, $1,817 in 2029 and $12,198 thereafter.
DEFERRED LEASING COSTS. Deferred leasing costs include capitalized brokerage costs and inducements associated with the successful negotiation of leases. We amortize deferred leasing costs, which are included in depreciation and amortization expense, and inducements, which are included as a reduction in rental income, on a straight line basis over the terms of the respective leases. Deferred leasing costs are included in other assets, net in our consolidated balance sheets. Deferred leasing costs totaled $59,286 and $62,980 at December 31, 2024 and 2023, respectively, and accumulated amortization of deferred leasing costs totaled $22,377 and $19,985 at December 31, 2024 and 2023, respectively. At December 31, 2024, the remaining weighted average amortization period is approximately 7.8 years. Future amortization of deferred leasing costs to be recognized during the current terms of our existing leases as of December 31, 2024 are estimated to be $6,799 in 2025, $6,280 in 2026, $5,199 in 2027, $4,418 in 2028, $3,238 in 2029 and $10,975 thereafter.
FAIR VALUE OF FINANCIAL INSTRUMENTS. We determine the estimated fair value of financial assets and liabilities using the three-tier fair value hierarchy established by accounting principles generally accepted in the United States, or GAAP, which prioritizes observable inputs in active markets when measuring fair value. The three levels of inputs that may be used to measure fair value in order of priority are as follows:
Level 1—Inputs include quoted prices in active markets for identical assets or liabilities that we have the ability to access.
Level 2—Inputs include quoted prices in markets that are less active or inactive or for which all significant inputs are observable, either directly or indirectly.
Level 3—Inputs include unobservable prices and are supported by little or no market activity and are significant to the overall fair value measurement.
REVENUE RECOGNITION. We are a lessor of medical office and life science properties, senior living communities and other healthcare related properties. Our leases provide our tenants with the contractual right to use and economically benefit from all of the premises demised under the leases; therefore, we have determined to evaluate our leases as lease arrangements.
Our leases provide for base rent payments and in addition may include variable payments. Rental income from operating leases, including any payments derived by index or market based indices, is recognized on a straight line basis over the lease term when we have determined that the collectability of substantially all of the lease payments is probable. Some of our leases have options to extend or terminate the lease exercisable at the option of our tenants, which are considered when determining the lease term. We do not include in our measurement of our lease receivables certain variable payments, including changes in the index or market based indices after the inception of the lease, certain tenant reimbursements and other income until the specific events that trigger the variable payments have occurred.
Certain of our leases contain non-lease components, such as property level operating expenses and capital expenditures reimbursed by our tenants as well as other required lease payments. We have determined that all of our leases qualify for the practical expedient to not separate the lease and non-lease components because (i) the lease components are operating leases and (ii) the timing and pattern of recognition of the non-lease components are the same as those of the lease components. We apply the Accounting Standards, or ASC, Codification Topic 842, Leases, to the combined component. Income derived by our leases is recorded in rental income in our consolidated statements of comprehensive income (loss).
Certain tenants are obligated to pay directly their obligations under their leases for insurance, real estate taxes and certain other expenses. These obligations, which have been assumed by the tenants under the terms of their respective leases, are not reflected in our consolidated financial statements. To the extent any tenant responsible for any such obligations under the applicable lease defaults on such lease or if it is deemed probable that the tenant will fail to pay for such obligations, we would record a liability for such obligations.
For the years ended December 31, 2024, 2023 and 2022, we recognized the rental income from our operating leases on a straight line basis over the term of each lease agreement. We recognized percentage rents when realizable and earned, which was generally during the fourth quarter of the year. For the years ended December 31, 2024, 2023 and 2022, percentage rents earned aggregated $3,435, $2,949 and $2,978, respectively.
For leases where we are the lessee, we recognize a right of use asset and a lease liability equal to the present value of the minimum lease payments with rental payments being applied to the lease liability and the right of use asset being amortized over the term of the lease. The right of use assets and related lease liabilities are included within other assets, net and other liabilities, respectively, within our consolidated balance sheets. In addition, we lease equipment at certain of our managed senior living communities. These leases are short term in nature, are cancelable with no fee or do not result in an annual expense in excess of our capitalization policy and, as a result, are not recorded on our consolidated balance sheets.
As of December 31, 2024, we owned 232 senior living communities that are managed by third party managers for our account. We derive our revenues at these managed senior living communities primarily from services our managers provide to residents on our behalf and we record revenues when the services are provided. We use the taxable REIT subsidiary, or TRS, structure authorized by the REIT Investment Diversification and Empowerment Act for our managed senior living communities.
Under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, the U.S. Department of Health and Human Services established a Provider Relief Fund. Subsequently, the American Rescue Plan Act, or ARPA, was enacted. Retention and use of the funds received under the CARES Act and ARPA are subject to certain terms and conditions. The terms and conditions require that the funds be utilized to compensate for lost revenues that are attributable to the COVID-19 pandemic and for eligible costs to prevent, prepare for and respond to the COVID-19 pandemic that are not covered by other sources. Further, fund recipients are required to be participating in Medicare at the time of distribution and are subject to certain other terms and conditions, including quarterly reporting requirements. In addition, fund recipients are required to have billed Medicare during 2019 and to continue to provide care after January 31, 2020 for diagnosis, testing or care for individuals with possible or actual COVID-19 cases. Any funds not used in accordance with the terms and conditions must be returned. We recognize income from government grants on a systematic and rational basis over the period in which we recognize the related expenses or loss of revenues for which the grants are intended to compensate when there is reasonable assurance that we will comply with the applicable terms and conditions of the grant and there is reasonable assurance that the grant will be received. During the years ended December 31, 2024, 2023 and 2022, we received $0, $1,581 and $605, respectively, in funds to be used to support the operations of our managed senior living communities. We have recognized $0, $1,581 and $4,327 as interest and other income in our consolidated statements of comprehensive income (loss) with respect to our senior housing operating portfolio, or SHOP, segment for the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, we have recognized all funds andno amount remained in other liabilities in our consolidated balance sheets.
PER COMMON SHARE AMOUNTS. We calculate basic earnings per common share by dividing net income (loss) by the weighted average number of our common shares of beneficial interest, $.01 par value, or our common shares, outstanding during the period. We calculate diluted earnings per common share using the more dilutive of the two class method or the treasury stock method. Unvested share awards and other potentially dilutive common shares, together with the related impact on earnings, are considered when calculating diluted earnings per share.
INCOME TAXES. We have elected to be taxed as a REIT under the United States Internal Revenue Code of 1986, as amended, and, as such, are generally not subject to federal and most state income taxation on our operating income provided we distribute our taxable income to our shareholders and meet certain organization and operating requirements. We do, however, lease our managed senior living communities to our wholly owned TRSs that, unlike most of our subsidiaries, file a separate consolidated federal corporate income tax return and are subject to federal and state income taxes. Our consolidated income tax provision includes the income tax provision related to the operations of our TRSs and certain state income taxes we incur despite our taxation as a REIT. Our current income tax expense (or benefit) fluctuates from period to period based primarily on the timing of our income, including gains on the disposition of properties or losses in a particular quarter.
The Income Taxes Topic of the Codification prescribes how we should recognize, measure and present in our consolidated financial statements uncertain tax positions that have been taken or are expected to be taken in a tax return. Tax benefits are recognized to the extent that it is “more likely than not” that a particular tax position will be sustained upon examination or audit. To the extent the “more likely than not” standard has been satisfied, the benefit associated with a tax position is measured as the largest amount that has a greater than 50% likelihood of being realized upon settlement. We classify interest and penalties related to uncertain tax positions, if any, in our consolidated financial statements as a component of general and administrative expense.
USE OF ESTIMATES. Preparation of these consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in these consolidated financial statements and related notes. The actual results could differ from these estimates. Significant estimates in the consolidated financial statements include purchase price allocations, useful lives of fixed assets and assessment of impairment of real estate and the related intangibles.
SEGMENT REPORTING. As of December 31, 2024, we operate in, and report financial information for, the followingtwo segments: our portfolio of medical office and life science properties, or our Medical Office and Life Science Portfolio, and SHOP. See Note 11 for further information regarding our reportable operating segments.
RECENT ACCOUNTING PRONOUNCEMENTS.
On December 14, 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, or ASU No. 2023-09, which requires public entities to enhance their annual income tax disclosures by requiring: (i) consistent categories and greater disaggregation of information in the rate reconciliation, and (ii) income taxes paid disaggregated by jurisdiction. ASU No. 2023-09 should be applied prospectively but entities have the option to apply it retrospectively to all prior periods presented in the consolidated financial statements. ASU No. 2023-09 is effective for annual periods beginning after December 15, 2024, with early adoption permitted. We expect to include additional disclosures in the notes to our consolidated financial statements as a result of the implementation of ASU No. 2023-09; however, these changes are not expected to have a material effect on our consolidated financial statements.
In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statements Expenses, or ASU No. 2024-03, which requires public entities to disclose specific expense categories such as employee compensation, depreciation and intangible asset amortization. These details must be presented in a tabular format in the notes to consolidated financial statements for both interim and annual reporting periods. ASU 2024-03 is required to be applied prospectively but can be applied retrospectively, and is effective for the first annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. We are currently evaluating the impact of ASU 2024-03 will have on our consolidated financial statements.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, or ASU No. 2023-07, which requires public entities, including those with a single reportable segment, to: (i) provide disclosures of significant segment expenses and other segment items if they are regularly provided to the chief operating decision maker, or the CODM, and included in each reported measure of segment profit or loss; (ii) provide all annual disclosures about a reportable segment’s profit or loss and assets currently required by ASC 280, Segment Reporting, in interim periods; and (iii) disclose the CODM’s title and position, as well as an explanation of how the CODM uses the reported measures and other disclosures. ASU No. 2023-07 does not change how a public entity identifies its operating segments, aggregates those operating segments or applies the quantitative thresholds to determine its reportable segments. We adopted the new standard effective December 31, 2024. As a result, we have included additional information related to the required disclosures in Note 11.
Note 3. Real Estate Investments
Acquisitions:
The table below represents the purchase price allocations (including net closing adjustments) of acquisitions for the years ended December 31, 2024, 2023 and 2022:
| Date | State | Type of Property | Number of Properties | Square Feet | Cash Paid (1) | Land | BuildingsandImprovements | AcquiredReal EstateLeases |
|---|---|---|---|---|---|---|---|---|
| Acquisitions during the year ended December 31, 2024: | ||||||||
| We did not acquire any properties during the year ended December 31, 2024. | ||||||||
| Acquisitions during the year ended December 31, 2023: | ||||||||
| We did not acquire any properties during the year ended December 31, 2023. | ||||||||
| Acquisitions during the year ended December 31, 2022: (2) | ||||||||
| July 2022 | California | Life Science | 1 | 88,508 | $75,105 | $15,774 | $45,249 | $14,082 |
(1)Cash paid includes closing costs.
(2)We have accounted for our 2022 acquisition as an acquisition of assets. We funded this acquisition using cash on hand.
Impairment:
We regularly evaluate our assets for indicators of impairment. Impairment indicators may include declining tenant or resident occupancy, weak or declining profitability from the property, decreasing tenant cash flows or liquidity, our decision to dispose of an asset before the end of its estimated useful life and legislative, market or industry changes that could permanently reduce the value of an asset. If indicators of impairment are present, we evaluate the carrying value of the affected assets by comparing it to the expected future undiscounted cash flows to be generated from those assets. The future cash flows are subjective and are based in part on assumptions regarding hold periods, market rents and terminal capitalization rates. If the sum of these expected future cash flows is less than the carrying value, we reduce the net carrying value of the asset to its estimated fair value.
During 2024, we recorded impairment charges of $70,734 to adjust the carrying value ofsix medical office and life science properties to their estimated fair value. We sold three of these medical office and life science properties in 2024. Three of these medical office and life science properties were classified as held for sale in our consolidated balance sheet as of December 31, 2024. These impairment charges, in aggregate, are included in impairment of assets in our consolidated statements of comprehensive income (loss).
During 2023, we recorded impairment charges of $14,034 to adjust the carrying value offour medical office and life science properties to their estimated fair value. We sold three of these medical office and life science properties in 2023. One of these medical office properties was classified as held for sale in our consolidated balance sheet as of December 31, 2023. During 2023, we also recorded impairment charges of $4,346 to adjust the carrying values oftwo senior living communities to their aggregate estimated fair value. We soldone of these senior living communities in 2023. These impairment charges, in aggregate, are included in impairment of assets in our consolidated statements of comprehensive income (loss).
Dispositions:
The table below represents the sale prices (excluding closing costs) of dispositions for the years ended December 31, 2024, 2023 and 2022. The sales of these properties do not represent significant dispositions, individually or in the aggregate, and we do not believe these sales represent a strategic shift in our business. As a result, the results of operations for these properties are included in continuing operations through the date of sale of such properties in our consolidated statements of comprehensive income (loss).
| Date of Sale · State · Type of Property · Number of Properties · Square Feet or Number of Units · Sales Price · Gain (Loss) on Sale | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Dispositions during the year ended December 31, 2024: | |||||||||
| March 2024 | Arizona | Medical Office | 1 | 126,084 | sq. ft. | $3,600 | $(5,874) | ||
| June 2024 | Texas | Medical Office | 1 | 94,137 | sq. ft. | 4,200 | (13,213) | ||
| July 2024 | Illinois and Minnesota | Medical Office | 2 | 205,673 | sq. ft. | 21,275 | 111 | ||
| November 2024 | Kansas | Life Science | 1 | 239,366 | sq. ft. | 6,600 | 38 | ||
| 5 | $35,675 | $(18,938) | |||||||
| Dispositions during the year ended December 31, 2023: | |||||||||
| February 2023 | Pennsylvania and South Carolina | Senior Living | 3 | — | units (1) | $2,800 | $293 | ||
| October 2023 | Pennsylvania | Medical Office | 1 | 30,866 | sq. ft. | 1,800 | 15 | ||
| October 2023 | Tennessee | Senior Living | 1 | — | units (1) | 2,830 | 627 | ||
| October 2023 | Maryland | Life Science | 1 | 58,880 | sq. ft. | 6,200 | (360) | ||
| November 2023 | Virginia | Senior Living | 1 | — | units (1) | 1,800 | 945 | ||
| December 2023 | South Carolina | Medical Office | 1 | 115,108 | sq. ft. | 3,450 | (1,255) | ||
| 8 | $18,880 | $265 | |||||||
| Dispositions during the year ended December 31, 2022: | |||||||||
| We did not dispose of any properties during the year ended December 31, 2022. | |||||||||
(1)These communities were closed prior to their respective dispositions.
During the year ended December 31, 2023, we recognized a gain of $940 related to the sales of skilled nursing bed licenses at certain of our senior living communities.
We classify all properties as held for sale in our consolidated balance sheets that meet the applicable criteria for that treatment as set forth in the Property, Plant and Equipment Topic of the Codification. As of December 31, 2024, we had 32 properties classified as held for sale as follows:
| Segment | Number of Properties | Real Estate Properties, Net |
|---|---|---|
| Medical Office and Life Science | 7 | $175,948 |
| SHOP | 6 | 47,535 |
| All Other - triple net leased senior living communities | 19 | 37,900 |
| 32 | $261,383 |
In January 2025, we sold three life science properties for a sales price of $159,025, excluding closing costs. As of December 31, 2024, these three properties were classified as held for sale. The net proceeds from the sale of these three properties will be used to partially redeem our outstanding senior secured notes due 2026. Additionally, in January and February 2025, we soldone life science property for a sales price of $16,800, excluding closing costs, andone senior living community for a sales price of $2,900, excluding closing costs, both of which were classified as held for sale as of December 31, 2024.
As of February 24, 2025, we had 26 properties under agreements or letters of intent to sell for an aggregate sales price of $219,580, excluding closing costs. The net proceeds from 19 of these properties, which have an expected aggregate sales price, excluding closing costs, of $142,100, will be used to partially redeem our outstanding senior secured notes due 2026, if the sales of such properties are completed. We may not complete the sales of any or all of the properties we currently plan to sell. Also, we may sell some or all of these properties at amounts that are less than currently expected and/or less than the carrying values of such properties, and we may incur losses on any such sales as a result. As of December 31, 2024, all 26 of these properties were classified as held for sale.
Investments and Capital Expenditures:
The following is a summary of capital expenditures, development, redevelopment and other activities for the periods presented:
| For the Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Medical Office and Life Science Portfolio capital expenditures: | |||
| Lease related costs (1) | $21,289 | $38,070 | $25,227 |
| Building improvements (2) | 6,002 | 12,984 | 11,955 |
| Recurring capital expenditures - Medical Office and Life Science Portfolio | 27,291 | 51,054 | 37,182 |
| SHOP fixed assets and capital improvements | 93,043 | 100,981 | 109,529 |
| Wellness centers lease related costs (1) | 20,618 | 9,721 | — |
| Total recurring capital expenditures | $140,952 | $161,756 | $146,711 |
| Development, redevelopment and other activities - Medical Office and Life Science Portfolio (3) | $3,012 | $9,244 | $48,390 |
| Development, redevelopment and other activities - SHOP (3) | 46,558 | 82,207 | 118,601 |
| Total development, redevelopment and other activities | $49,570 | $91,451 | $166,991 |
| Capital expenditures by segment: | |||
| Medical Office and Life Science Portfolio | $30,303 | $60,298 | $85,572 |
| SHOP | 139,601 | 183,188 | 228,130 |
| All Other - wellness centers | 20,618 | 9,721 | — |
| Total capital expenditures | $190,522 | $253,207 | $313,702 |
(1)Includes capital expenditures to improve tenants' space or amounts paid directly to tenants to improve their space and other leasing related costs, such as brokerage commissions and tenant inducements.
(2)Includes capital expenditures to replace obsolete building components that extend the useful life of existing assets or other improvements to increase the marketability of the property.
(3)Includes capital expenditures that reposition a property or result in new sources of revenue.
Other:
In September 2022, certain of our managed senior living communities located in Florida experienced hurricane related damage. We carry comprehensive property, casualty, flood and business interruption insurances that we anticipate will cover our losses at these senior living communities, subject to a deductible. During the year ended December 31, 2022, we incurred total losses of $11,253 related to the property damage sustained and deductible incurred. For the year ended December 31, 2022, we recognized a loss of $7,635 for the involuntary conversion of nonmonetary assets and wrote off a portion of the net book value of the damaged assets and included this amount in our consolidated statements of comprehensive income (loss). During the year ended December 31, 2022, we received $14,466 in cash from our insurance provider, and as such, we have recovered the total losses of $11,253 incurred during the year ended December 31, 2022. The loss of $7,635 for the involuntary conversion of nonmonetary assets, recovery of those $7,635 in losses and the deductible of $3,618 are included in property operating expenses in our consolidated statements of comprehensive income (loss). We received $1,698, $534 and $3,213 in cash in excess of our losses during the years ended December 31, 2024, 2023 and 2022, respectively. These amounts are included in other liabilities in our consolidated balance sheets.
Equity Method Investments in Unconsolidated Joint Ventures:
As of December 31, 2024, we had equity investments in unconsolidated joint ventures as follows:
| Equity Method Investments in Joint Venture | DHC Ownership | DHC Carrying Value of Investment at December 31, 2024 | Number of Properties | State | Square Feet |
|---|---|---|---|---|---|
| Seaport Innovation LLC | 10% | $81,949 | 1 | MA | 1,134,479 |
| The LSMD Fund REIT LLC | 20% | 44,910 | 10 | CA, MA, NY, TX, WA | 1,068,763 |
| $126,859 | 11 | 2,203,242 | |||
The following table provides a summary of the mortgage debts of these joint ventures as of December 31, 2024:
| Joint Venture | Coupon Rate | Maturity Date | Principal Balance (1) |
|---|---|---|---|
| Mortgage Notes Payable (secured by one property in Massachusetts) (2)(3) | 3.53% | 11/6/2028 | $620,000 |
| Mortgage Notes Payable (secured by nine properties in five states) (4) | 3.46% | 2/11/2032 | 189,800 |
| Mortgage Notes Payable (secured by one property in California) (4)(5) | 6.38% | 2/9/2025 | 266,825 |
| Weighted Average / Total | 4.22% | $1,076,625 |
(1)Amounts are not adjusted for our minority equity interest.
(2)We provide certain guaranties on this debt.
(3)This mortgage loan requires interest only payments until the anticipated repayment date on August 6, 2026, at which time all accrued and unpaid interest along with the principal balance of $620,000 is expected to be repaid. This mortgage loan matures on November 6, 2028 and any unpaid principal from the anticipated repayment date through the maturity date bears interest at a variable rate of the greater of 6.53% or the then effective U.S. swap rate terminating on the maturity date plus 5.00%.
(4)The debt securing these properties is non-recourse to us.
(5)The joint venture has exercised its option to extend the maturity date of this mortgage loan by one year to February 9, 2026, and this mortgage loan requires interest to be paid at an annual rate of the one month term secured overnight financing rate, or SOFR, plus a premium of 1.90%. This joint venture has also purchased an interest rate cap through February 2026 with a SOFR strike rate equal to 5.74%. The maturity date of this mortgage loan is subject toone remainingone-year extension option.
We account for the Seaport JV using the equity method of accounting under the fair value option. In June 2022, we sold a 10% equity interest from our then remaining 20% equity interest in the Seaport JV to an existing joint venture investor for $108,000, before closing costs and other adjustments. We received net proceeds of $108,424 from this transaction, which included working capital prorations and formation costs. We recognized a net loss on sale of $1,428 related to this transaction during the year ended December 31, 2022, which is included in (loss) gain on sale of properties in our consolidated statements of comprehensive income (loss). After giving effect to this sale, we continue to own a 10% equity interest in this joint venture. Our initial investment amount was based on a property valuation of $1,700,000, less $620,000 of existing mortgage debts on the property that this joint venture assumed.
In January 2022, we entered into the LSMD JV withtwo unrelated third party institutional investors. We sold equity interests in this joint venture to those investors for aggregate proceeds, before closing costs and other adjustments, of approximately $653,300. We deconsolidated the net assets of these properties effective as of the date of the sale and recognized a net gain on sale of $322,468 related to this transaction during the year ended December 31, 2022, which is included in (loss) gain on sale of properties in our consolidated statements of comprehensive income (loss). The equity interests that the investors acquired from us equaled 41% and 39%, respectively, of the total equity interests in the joint venture, and we retained a 20% equity interest in the joint venture. Following the sale, we account for this joint venture using the equity method of accounting under the fair value option. The initial investment amounts were based upon a property valuation of approximately $702,500, less approximately $456,600 of secured debt on the properties incurred by this joint venture.
We recognized changes in the fair value of our investments in our unconsolidated joint ventures of $(7,550), $(20,461) and $6,055 during the years ended December 31, 2024, 2023 and 2022, respectively. These amounts are included in equity in net earnings (losses) of investees in our consolidated statements of comprehensive income (loss). See Note 10 for more information regarding the valuation of our investment in these joint ventures.
Equity Method Investment in AlerisLife:
As of December 31, 2024, we owned approximately 34.0% of the outstanding common shares of AlerisLife Inc., or AlerisLife. We do not control the activities that are most significant to AlerisLife and, as a result, we account for our non-controlling interest in AlerisLife using the equity method of accounting.
As of December 31, 2024, our investment in AlerisLife had a carrying value of $24,590. The cost basis of our investment in AlerisLife exceeded our proportionate share of AlerisLife's total stockholders' equity book value on the date of acquisition of our initial interest in AlerisLife, which was February 16, 2024, by an aggregate of $29,500. As required under GAAP, we are amortizing this difference to equity in earnings of an investee over 21 years, the weighted average remaining useful life of the real estate assets owned by AlerisLife and the intangible contract asset with us as of the date of acquisition. We recorded amortization of the basis difference of $1,228 for the year ended December 31, 2024. We recognized income of $7,919 related to our investment in AlerisLife for the year ended December 31, 2024. These amounts are included in equity in net earnings (losses) of investees in our consolidated statements of comprehensive income (loss). See Notes 2 and 8 for more information regarding our investment in AlerisLife.
Note 4. Leases
We are a lessor of medical office and life science properties, senior living communities and other healthcare related properties. Our leases provide our tenants with the contractual right to use and economically benefit from all of the premises demised under the leases; therefore, we have determined to evaluate our leases as lease arrangements.
Our leases provide for base rent payments and, in addition, may include variable payments. Rental income from operating leases, including any payments derived by index or market based indices, is recognized on a straight line basis over the lease term when we have determined that the collectability of substantially all of the lease payments is probable. Some of our leases have options to extend or terminate the lease exercisable at the option of our tenants, which are considered when determining the lease term.
We increased rental income to record revenue on a straight line basis by $1,445 and $8,916 for the years ended December 31, 2024 and 2022, respectively. We decreased rental income to record revenue on a straight line basis by $1,095 for the year ended December 31, 2023. Rents receivable, excluding receivables related to our properties classified as held for sale, if any, include $69,814 and $75,306 of straight line rent receivables at December 31, 2024 and 2023, respectively, and are included in other assets, net in our consolidated balance sheets.
We do not include in our measurement of our lease receivables certain variable payments, including changes in the index or market based indices after the inception of the lease, certain tenant reimbursements and other income until the specific events that trigger the variable payments have occurred. Such payments totaled $48,873, $51,367 and $47,669 for the years ended December 31, 2024, 2023 and 2022, respectively, of which tenant reimbursements totaled $45,255, $48,215 and $44,470, respectively.
The following table presents our operating lease maturity analysis, excluding lease payments from properties classified as held for sale, if any, as of December 31, 2024:
| Year | Amount |
|---|---|
| 2025 | $170,570 |
| 2026 | 165,463 |
| 2027 | 145,436 |
| 2028 | 124,635 |
| 2029 | 107,135 |
| Thereafter | 455,731 |
| Total | $1,168,970 |
Right of Use Asset and Lease Liability. For leases where we are the lessee, we recognize a right of use asset and a lease liability equal to the present value of the minimum lease payments with rental payments being applied to the lease liability and the right of use asset being amortized over the term of the lease. The values of the right of use assets and related liabilities representing our future obligation under the respective lease arrangements for which we are the lessee were $20,025 and $20,411, respectively, as of December 31, 2024, and $23,366 and $23,748, respectively, as of December 31, 2023. The right of use assets and related lease liabilities are included within other assets, net andother liabilities, respectively, within our consolidated balance sheets. In addition, we lease equipment at certain of our managed senior living communities. These leases are short term in nature, are cancelable with no fee or do not result in an annual expense in excess of our capitalization policy and, as a result, are not recorded on our consolidated balance sheets.
Note 5. Shareholders' Equity
We have common shares available for issuance under the terms of our equity compensation plan adopted in 2012, as amended, or the 2012 Plan. During the years ended December 31, 2024, 2023 and 2022, we awarded to our officers and certain other employees of The RMR Group LLC, or RMR, and certain employees of AlerisLife annual share awards of 881,767,800,000 and 707,000 of our common shares, respectively, valued at $2,954, $1,864 and $919, in aggregate, respectively. In accordance with our Trustee compensation arrangements, we also awarded each of our then Trustees 37,037 common shares with an aggregate value of $630 ($90 per Trustee),20,000 common shares with an aggregate value of $244 ($35 per Trustee) and 20,000 common shares with an aggregate value of $300 ($43 per Trustee) in 2024, 2023 and 2022, respectively. Also in September 2023, in connection with the election ofone of our Trustees, we awarded 20,000 of our common shares to this Trustee with a value of $45. The values or numbers, as applicable, of the share awards were based upon the closing price of our common shares trading on The Nasdaq Stock Market LLC, or Nasdaq, on the dates of awards. The common shares awarded to our Trustees vested immediately. The common shares awarded to our officers and certain other employees of RMR and certain employees of AlerisLife vest infive equal annual installments beginning on the date of award. We recognize share forfeitures as they occur and include the value of awarded shares in general and administrative expenses in our consolidated statements of comprehensive income (loss) ratably over the vesting period. At December 31, 2024,1,090,392 of our common shares remain available for issuance under the 2012 Plan.
A summary of shares awarded, forfeited, vested and unvested under the terms of the 2012 Plan from January 1, 2022 to December 31, 2024 is as follows:
| Number of Shares | Weighted AverageAward DateFair Value | |
|---|---|---|
| Unvested shares at December 31, 2021 | 845,620 | $4.07 |
| Shares awarded in 2022 | 847,000 | $1.44 |
| Shares vested / forfeited in 2022 | (576,620) | $3.24 |
| Unvested shares at December 31, 2022 | 1,116,000 | $2.50 |
| Shares awarded in 2023 | 960,000 | $2.24 |
| Shares vested / forfeited in 2023 | (847,800) | $2.53 |
| Unvested shares at December 31, 2023 | 1,228,200 | $2.28 |
| Shares awarded in 2024 | 1,141,026 | $3.14 |
| Shares vested / forfeited in 2024 | (1,049,225) | $2.54 |
| Unvested shares at December 31, 2024 | 1,320,001 | $2.80 |
The 1,320,001 unvested shares as of December 31, 2024 are scheduled to vest as follows:
| Unvested Shares | |
|---|---|
| 2025 | 461,850 |
| 2026 | 384,657 |
| 2027 | 297,450 |
| 2028 | 176,044 |
| Total | 1,320,001 |
As of December 31, 2024, the estimated future compensation for the unvested shares was $3,323 based on the adjusted award date fair value of these shares. At December 31, 2024, the weighted average period over which the compensation expense will be recorded is approximately 1.9 years.
During the years ended December 31, 2024, 2023 and 2022, we recorded share based compensation expense of $2,747, $1,840 and $1,733, respectively.
During the years ended December 31, 2024, 2023 and 2022, we purchased an aggregate of 268,221,184,344 and 133,752 of our common shares, respectively, from certain of our Trustees and officers and certain other current and former officers and employees of RMR and certain employees of AlerisLife, in satisfaction of tax withholding and payment obligations in connection with the vesting of awards of our common shares.
A summary of cash distributions paid to common shareholders, for federal income tax purposes, are as follows for the periods presented:
| Annual Per · Characterization of Distribution | |||||
|---|---|---|---|---|---|
| Share · Total · Ordinary · Capital · Return of | |||||
| Year | Distribution | Distribution | Income | Gain | Capital |
| 2024 | $0.04 | $9,627 | —% | —% | 100.0% |
| 2023 | $0.04 | $9,595 | —% | —% | 100.0% |
| 2022 | $0.04 | $9,568 | —% | 14.0% | 86.0% |
On January 16, 2025, we declared a quarterly distribution to common shareholders of record on January 27, 2025 of $0.01 per share, or approximately $2,413. We paid this distribution on February 20, 2025 using cash on hand.
Note 6. Senior Living Community Management Agreements
Our managed senior living communities are operated by third parties pursuant to management agreements. Five Star Senior Living, or Five Star, which is an operating division of AlerisLife, manages 118 of our SHOP communities, and we lease nearly all of our senior living communities managed by third party managers, to our TRSs.
Management Arrangements with Five Star. We and Five Star are parties to an amended and restated master management agreement, or the Master Management Agreement, for the senior living communities that Five Star manages for us. Pursuant to an amended and restated guaranty agreement, AlerisLife guarantees the payment and performance of each of its applicable subsidiary’s obligations under the applicable management agreements.
Pursuant to the Master Management Agreement, Five Star receives a management fee equal to 5% of the gross revenues realized at the applicable senior living communities plus reimbursement for its direct costs and expenses related to such communities. Five Star may receive an annual incentive fee equal to 15% of the amount by which the annual EBITDA of all communities on a combined basis exceeds the target EBITDA for all communities on a combined basis for such calendar year. The target EBITDA for those senior living communities on a combined basis is increased annually based on the greater of the annual increase of the consumer price index, or CPI, or 2%, plus 6% of any capital investments funded at the managed senior living communities on a combined basis in excess of the target capital investment. Unless otherwise agreed, the target capital investment increases annually based on the greater of the annual increase of CPI or 2%. Any senior living communities that are undergoing a major renovation or repositioning are excluded from the calculation of the incentive fee.
The Master Management Agreement expires in 2036, subject to Five Star's right to extend fortwo consecutive five year terms if Five Star achieves certain performance targets for the combined managed communities portfolio, unless earlier terminated. Pursuant to the Master Management Agreement, beginning in 2025, we have the right to terminate up to 10% of the senior living communities that Five Star is continuing to manage, based on total revenues per year for failure to meet 80% of a target EBITDA for the applicable period.
In connection with ABP Trust’s acquisition of AlerisLife on March 20, 2023, we amended the Master Management Agreement to eliminate any change of control default or event of default provisions effective upon the consummation of the AlerisLife acquisition by ABP Trust. See Note 8 for further information regarding ABP Trust’s acquisition of AlerisLife.
In 2021, we completed the transition of 107 of the 108 senior living communities, containing 7,340 living units, from Five Star to other third party managers. In January 2025, we sold a closed senior living community that had previously been managed by Five Star. We recorded $2,096 of costs that we incurred related to retention and other transition costs for the year ended December 31, 2022 to acquisition and certain other transaction related costs in our consolidated statements of comprehensive income (loss).
Our Senior Living Communities Managed by Five Star. Five Star managed 118,119 and 119 of our senior living communities as of December 31, 2024, 2023 and 2022, respectively. We lease our senior living communities that are managed by Five Star to our TRSs, and Five Star manages these communities pursuant to the Master Management Agreement. Effective October 31, 2022, Five Star ceased managing an active adult community we own located in Plano, TX, and RMR assumed management of that community pursuant to our property management agreement with RMR. We paid Five Star a termination fee of $350 in connection with the termination of Five Star's management of this community.
We incurred management fees payable to Five Star of $42,474, $40,119 and $37,037 for the years ended December 31, 2024, 2023 and 2022, respectively. For the years ended December 31, 2024, 2023 and 2022, $40,212, $37,436 and $33,737, respectively, of the total management fees were expensed to property operating expenses in our consolidated statements of comprehensive income (loss) and $2,262, $2,683 and $3,300, respectively, were capitalized in our consolidated balance sheets. The amounts capitalized are being depreciated over the estimated useful lives of the related capital assets.
Prior to the sale of their Ageility business to Fox Rehabilitation on June 17, 2024, Five Star also provided certain other services to residents at some of the senior living communities it manages for us, such as rehabilitation services. At senior living communities Five Star manages for us where Five Star provided rehabilitation services on an outpatient basis, the residents, third party payers or government programs paid Five Star for those rehabilitation services. At senior living communities Five Star manages for us where Five Star provided both inpatient and outpatient rehabilitation services, we generally paid Five Star for those rehabilitation services and charges for these services were included in amounts charged to residents, third party payers or government programs. During 2023, Five Star closed all inpatient clinics and as such we do not expect to incur these fees to Five Star in the future. We incurred fees of $0, $1,213 and $6,289 for the years ended December 31, 2024, 2023 and 2022, respectively, with respect to rehabilitation services Five Star provided at our senior living communities that are payable by us. These amounts are included in property operating expenses in our consolidated statements of comprehensive income (loss).
Since January 1, 2022, we sold certain senior living communities that were then managed by Five Star. We and Five Star terminated our management agreements for these senior living communities in connection with these sales. See Note 3 for further information regarding these sales.
We lease space to Five Star at certain of our senior living communities, which, prior to June 17, 2024, Five Star used to provide certain outpatient rehabilitation and wellness services through the Ageility branded business. Beginning on June 17, 2024, Five Star subleases this space to a subsidiary of Fox Rehabilitation, which acquired the Ageility branded business from AlerisLife on that date.
Our Senior Living Communities Managed by Other Third Party Managers. As of December 31, 2024, 2023 and 2022, respectively, our other third party managers managed 114,113 and 111 of our senior living communities. The terms of the management agreements with the other third party managers are generally as follows: the other third party managers will receive a management fee equal to 5% to 6% of the gross revenues realized at the applicable senior living communities plus reimbursement for direct costs and expenses related to such communities. These agreements generally also provide for the other third party managers to earn a minimum base fee for a portion of the term of the agreement. Additionally, the other third party managers have the ability to earn incentive fees equal to 15% to 25% of the amount by which EBITDA of the applicable communities exceeds the target EBITDA for the applicable communities. The other third party managers can also earn a construction supervision fee ranging between 3% and 5% of construction costs.
The initial terms of the management agreements with the other third party managers are generally five years, subject to automatic extensions of successive terms oftwo years each unless earlier terminated or timely notice of nonrenewal is delivered. The management agreements with the other third party managers also generally provide us with the right to terminate the management agreements for communities that do not earn 70% to 80% of the target EBITDA for such communities, after an agreed upon stabilized period.
In March 2024, we terminated our management agreement with one of our third party managers which managed 13 of our communities located in Wisconsin and Illinois and transitioned these communities to another third party manager with which we have an existing relationship. The terms of the management agreement for these communities are generally consistent with the terms of the existing management agreements with our other third party managers. We paid transition costs, including termination and other fees, of $2,228 related to the transition of these communities for the year ended December 31, 2024.
We incurred management fees payable to our other third party managers of $23,283, $21,863 and $20,739 for the years ended December 31, 2024, 2023 and 2022, respectively. Additionally, we incurred incentive fees to certain of our other third party operators of $241 during the year ended December 31, 2024. These amounts are included in property operating expenses in our consolidated statements of comprehensive income (loss).
The following table presents residents fees and services revenue from all of our managed senior living communities disaggregated by the type of contract and payer:
| Year Ended December 31, | |||
|---|---|---|---|
| Revenue from contracts with customers: | 2024 | 2023 | 2022 |
| Basic housing and support services | $972,307 | $915,528 | $806,500 |
| Medicare and Medicaid programs | 100,341 | 89,613 | 82,106 |
| Private pay and other third party payer SNF services | 171,741 | 146,767 | 134,220 |
| Total residents fees and services | $1,244,389 | $1,151,908 | $1,022,826 |
Note 7. Business and Property Management Agreements with RMR
We haveno employees. The personnel and various services we require to operate our business are provided to us by RMR. We havetwo agreements with RMR to provide management services to us: (1) a business management agreement, which relates to our business generally; and (2) a property management agreement, which relates to the property level operations of many of our properties, including our medical office and life science properties, and major renovation or repositioning activities at our senior living communities that we may request RMR to manage from time to time. See Note 8 for further information regarding our relationship, agreements and transactions with RMR.
Management Agreements with RMR. Our management agreements with RMR provide for an annual base management fee, an annual incentive management fee and property management and construction supervision fees, payable in cash, among other terms:
Base Management Fee. The annual base management fee payable to RMR by us for each applicable period is equal to the lesser of:
the sum of (a)0.5% of the daily weighted average of the aggregate book value of our real estate assets owned by us or our subsidiaries as of October 12, 1999, or the Transferred Assets, plus (b)0.7% of the average aggregate historical cost of our real estate investments excluding the Transferred Assets up to $250,000, plus (c)0.5% of the average aggregate historical cost of our real estate investments excluding the Transferred Assets exceeding $250,000; and
the sum of (a)0.7% of the average closing price per share of our common shares on the stock exchange on which such shares are principally traded during such period, multiplied by the average number of our common shares outstanding during such period, plus the daily weighted average of the aggregate liquidation preference of each class of our preferred shares outstanding during such period, plus the daily weighted average of the aggregate principal amount of our consolidated indebtedness during such period, or, together, our Average Market Capitalization, up to $250,000, plus (b)0.5% of our Average Market Capitalization exceeding $250,000.
The average aggregate historical cost of our real estate investments includes our consolidated assets invested, directly or indirectly, in equity interests in or loans secured by real estate and personal property owned in connection with such real estate (including acquisition related costs and costs which may be allocated to intangibles or are unallocated), all before reserves for depreciation, amortization, impairment charges or bad debts or other similar non-cash reserves.
Incentive Management Fee. The incentive management fee which may be earned by RMR for an annual period is calculated as follows:
An amount, subject to a cap, based on the value of our common shares outstanding, equal to 12.0% of the product of:
our equity market capitalization on the last trading day of the year immediately prior to the relevant three year measurement period, and
the amount (expressed as a percentage) by which the total return per share, as defined in the business management agreement and further described below, of our common shareholders (i.e., share price appreciation plus dividends) exceeds the total shareholder return of the applicable market index, or the benchmark return per share, for the relevant measurement period. The MSCI U.S. REIT/Health Care REIT Index is the applicable benchmark index.
For purposes of the total return per share of our common shareholders, share price appreciation for a measurement period is determined by subtracting (1) the closing price of our common shares on Nasdaq on the last trading day of the year immediately before the first year of the applicable measurement period, or the initial share price, from (2) the average closing price of our common shares on the 10 consecutive trading days having the highest average closing prices during the final 30 trading days in the last year of the measurement period.
The calculation of the incentive management fee (including the determinations of our equity market capitalization, initial share price and the total return per share of our common shareholders) is subject to adjustments if we issue or repurchase our common shares, or if our common shares are forfeited, during the measurement period.
No incentive management fee is payable by us unless our total return per share during the measurement period is positive.
The measurement periods arethree year periods ending with the year for which the incentive management fee is being calculated.
If our total return per share exceeds 12.0% per year in any measurement period, the benchmark return per share is adjusted to be the lesser of the total shareholder return of the applicable market index for such measurement period and 12.0% per year, or the adjusted benchmark return per share. In instances where the adjusted benchmark return per share applies, the incentive management fee will be reduced if our total return per share is between 200 basis points and 500 basis points below the applicable market index in any year, by a low return factor, as defined in the business management agreement, and there will beno incentive management fee paid if, in these instances, our total return per share is more than 500 basis points below the applicable market index in any year, determined on a cumulative basis (i.e. between 200 basis points and 500 basis point per year multiplied by the number of years in the measurement period and below the applicable market index).
The incentive management fee is subject to a cap. The cap is equal to the value of the number of our common shares which would, after issuance, represent 1.5% of the number of our common shares then outstanding multiplied by the average closing price of our common shares during the 10 consecutive trading days having the highest average closing prices during the final 30 trading days of the relevant measurement period.
Incentive management fees we paid to RMR for any period may be subject to “clawback” if our consolidated financial statements for that period are restated due to material non-compliance with any financial reporting requirements under the securities laws as a result of the bad faith, fraud, willful misconduct or gross negligence of RMR and the amount of the incentive management fee we paid was greater than the amount we would have paid based on the restated consolidated financial statements.
We did not incur any incentive management fee pursuant to our business management agreement for the years ended December 31, 2024, 2023 or 2022.
Property Management and Construction Supervision Fees. The property management fees payable to RMR by us for each applicable period are equal to 3.0% of gross collected rents and the construction supervision fees payable to RMR by us for each applicable period are equal to 5.0% of construction costs. Pursuant to our property management agreement with RMR, RMR provides oversight of any major capital projects and repositionings at our senior living communities, including our senior living communities which Five Star is continuing to manage, and RMR receives the same fee previously paid to Five Star for such services, which is equal to 3.0% of the cost of any such major capital project or repositioning.
Expense Reimbursement. We are generally responsible for all our operating expenses, including certain expenses incurred or arranged by RMR on our behalf. We are generally not responsible for payment of RMR's employment, office or administrative expenses incurred to provide management services to us, except for the employment and related expenses of RMR's employees assigned to work exclusively or partly at our properties, our share of the wages, benefits and other related costs of RMR's centralized accounting personnel, our share of RMR's costs for providing our internal audit function, or as otherwise agreed. Our property level operating expenses are generally incorporated into the rents charged to our tenants, including certain payroll and related costs incurred by RMR.
Term. Our management agreements with RMR have terms that end on December 31, 2044, and automatically extend on December 31st of each year for an additional year, so that the terms of our management agreements thereafter end on the 20th anniversary of the date of the extension.
Termination Rights. We have the right to terminate one or both of our management agreements with RMR: (i) at any time on 60 days' written notice for convenience, (ii) immediately on written notice for cause, as defined therein, (iii) on written notice given within 60 days after the end of an applicable calendar year for a performance reason, as defined therein, and (iv) by written notice during the 12 months following a change of control of RMR, as defined therein. RMR has the right to terminate the management agreements for good reason, as defined therein.
Termination Fee. If we terminateone or both of our management agreements with RMR for convenience, or if RMR terminatesone or both of our management agreements for good reason, we have agreed to pay RMR a termination fee in an amount equal to the sum of the present values of the monthly future fees, as defined therein, for the terminated management agreement(s) for the term that was remaining prior to such termination, which, depending on the time of termination would be between 19 and 20 years. If we terminateone or both of our management agreements with RMR for a performance reason, we have agreed to pay RMR the termination fee calculated as described above, but assuming a 10 year term was remaining prior to the termination. We are not required to pay any termination fee if we terminate our management agreements with RMR for cause or as a result of a change of control of RMR.
Transition Services. RMR has agreed to provide certain transition services to us for 120 days following an applicable termination by us or notice of termination by RMR, including cooperating with us and using commercially reasonable efforts to facilitate the orderly transfer of the management and real estate investment services provided under our business management agreement and to facilitate the orderly transfer of the management of the managed properties under our property management agreement, as applicable.
Vendors. Pursuant to our management agreements with RMR, RMR may from time to time negotiate on our behalf with certain third party vendors and suppliers for the procurement of goods and services to us. As part of this arrangement, we may enter agreements with RMR and other companies to which RMR or its subsidiaries provide management services for the purpose of obtaining more favorable terms from such vendors and suppliers.
Investment Opportunities. Under our business management agreement with RMR, we acknowledge that RMR may engage in other activities or businesses and act as the manager to any other person or entity (including other REITs) even though such person or entity has investment policies and objectives similar to ours and we are not entitled to preferential treatment in receiving information, recommendations and other services from RMR.
For the years ended December 31, 2024, 2023 and 2022, the business management fees, property management fees and construction supervision fees and expense reimbursements recognized in our consolidated financial statements were as follows:
| Financial Statement Line Item · Year Ended December 31, | ||||
|---|---|---|---|---|
| 2024 · 2023 · 2022 | ||||
| Pursuant to business management agreement: | ||||
| Business management fees | General and administrative expenses (1) | $16,468 | $13,965 | $16,646 |
| Pursuant to property management agreement (2): | ||||
| Property management fees | Property operating expenses | $5,683 | $5,686 | $5,657 |
| Construction supervision fees | Building and improvements (3) | 2,005 | 3,200 | 4,672 |
| $7,688 | $8,886 | $10,329 | ||
| Expense Reimbursement: | ||||
| Property level expenses | General and administrative expenses | $304 | $288 | $243 |
| Property level expenses | Property operating expenses | 14,719 | 14,299 | 12,658 |
| $15,023 | $14,587 | $12,901 | ||
(1)The net business management fees we recognized for the years ended December 31, 2024, 2023 and 2022 reflect a reduction of $2,974 for each of those years for the amortization of the liability we recorded in connection with our former investment in RMR Inc.
(2)The net property management and construction supervision fees we recognized for the years ended December 31, 2024, 2023 and 2022 reflect a reduction of $797 for each of those years for the amortization of the liability we recorded in connection with our former investment in RMR Inc., as further described in Note 8.
(3)Amounts capitalized as building improvements are depreciated over the estimated useful lives of the related capital assets.
In January 2025, in connection with a $100,000 credit agreement and related security agreement entered into by RMR and certain of its subsidiaries with Citibank, N.A., or Citibank, and the other lenders party thereto, we consented to the pledge and assignment of RMR’s interest in our management agreements under the security agreement. Pursuant to the consent, we agreed, among other things, that upon notice that an event of default under the RMR credit agreement has occurred and is continuing, we will continue to make all payments under our management agreements in accordance with the instructions of Citibank, and that if there is an event of default by RMR under our management agreements that would allow us to terminate or suspend our obligations, we will not terminate or suspend without notice to Citibank and provide Citibank 30 days to cure the default on RMR’s behalf. The consent was approved by our Independent Trustees.
Management Agreements between our Joint Ventures and RMR. We havetwo separate joint venture arrangements with third party institutional investors, the Seaport JV and the LSMD JV. RMR provides management services to both of these joint ventures. Our joint ventures are not our consolidated subsidiaries and, as a result, we are not obligated to pay management fees to RMR under our management agreements with RMR for the services it provides regarding the joint ventures. We wholly owned the 10 medical office and life science properties included in the LSMD JV until the contribution of these properties to the LSMD JV in January 2022, and we paid management fees to RMR for the management services it provided to us for those properties until the contribution of those properties to the LSMD JV.
Note 8. Related Person Transactions
We have relationships and historical and continuing transactions with RMR, RMR Inc., AlerisLife (including Five Star), and others related to them, including other companies to which RMR or its subsidiaries provide management services and some of which have trustees, directors or officers who are also our Trustees or officers. RMR is a majority owned subsidiary of RMR Inc. The Chair of our Board of Trustees and one of our Managing Trustees, Adam D. Portnoy, is the sole trustee, an officer and the controlling shareholder of ABP Trust, which is the controlling shareholder of RMR Inc., chair of the board of directors, a managing director and the president and chief executive officer of RMR Inc., an officer and employee of RMR and, until the acquisition of AlerisLife by ABP Trust on March 20, 2023, the chair of the board of directors and a managing director of AlerisLife, and currently the sole director of AlerisLife. Christopher J. Bilotto, our other Managing Trustee and President and Chief Executive Officer, and Matthew C. Brown, our Chief Financial Officer and Treasurer, are also officers and employees of RMR. Jennifer B. Clark, our Secretary and former Managing Trustee, also serves as a managing director and the executive vice president, general counsel and secretary of RMR Inc., an officer and employee of RMR, an officer of ABP Trust and secretary of AlerisLife and, until March 20, 2023, a managing director of AlerisLife. Jeffrey C. Leer, the president and chief executive officer of AlerisLife, is an executive officer of RMR. Some of our Independent Trustees also serve as independent trustees of other public companies to which RMR or its subsidiaries provide management services. Adam D. Portnoy serves as the chair of the board and as a managing trustee of these companies. Other officers of RMR, including Ms. Clark and certain of our officers, serve as managing trustees, or officers of certain of these companies. In addition, officers of RMR and RMR Inc. serve as our officers and officers of other companies to which RMR or its subsidiaries provide management services. As of December 31, 2024, ABP Trust and Adam D. Portnoy owned 9.8% of our outstanding common shares.
AlerisLife. Until March 20, 2023, we were AlerisLife's largest stockholder, owning approximately 31.9% of AlerisLife's outstanding common shares, and ABP Acquisition LLC, or ABP Acquisition, a subsidiary of ABP Trust, together with ABP Trust, owned approximately 6.1% of AlerisLife's outstanding common shares. Five Star is an operating division of AlerisLife. Five Star manages certain of the senior living communities we own pursuant to the Master Management Agreement. RMR provides management services to both us and AlerisLife. AlerisLife participates in our property insurance program for the senior living communities AlerisLife owns. The premiums AlerisLife pays for this coverage are allocated pursuant to a formula based on the profiles of the properties included in the program. See Note 6 for further information regarding our relationships, agreements and transactions with AlerisLife (including Five Star) and Note 2 for further information regarding our investment in AlerisLife.
On February 2, 2023, AlerisLife entered into an Agreement and Plan of Merger, or the ALR Merger Agreement, with certain subsidiaries of ABP Trust, pursuant to which ABP Trust acquired all of the publicly held outstanding AlerisLife common shares at a price of $1.31 per share, or the Tender Offer Price, by tender offer.
In connection with the ALR Merger Agreement, on February 2, 2023, we agreed to tender all the AlerisLife common shares that we and our subsidiary then owned into the tender offer at the Tender Offer Price, subject to the right, but not the obligation, to purchase, on or before December 31, 2023, AlerisLife common shares at the Tender Offer Price, and otherwise pursuant to a stockholders agreement to be entered into at the time of any such purchase. On December 20, 2023, we and ABP Trust extended our right to purchase AlerisLife common shares until March 31, 2024.
On February 16, 2024, we exercised this purchase right and acquired, together with our applicable TRS, approximately 34.0% of the then outstanding AlerisLife common shares from ABP Trust at the Tender Offer Price, for a total purchase price of $15,459, including transaction related costs, and we, our applicable TRS, ABP Trust and AlerisLife entered into a stockholders agreement. Following this acquisition, ABP Trust owns the remaining approximate 66.0% of AlerisLife.
In connection with AlerisLife's sale of its Ageility branded business to a subsidiary of Fox Rehabilitation on June 17, 2024, we approved Five Star's sublease to a subsidiary of Fox Rehabilitation of space at certain of our senior living communities, which is used to provide certain outpatient rehabilitation and wellness services.
On February 14, 2025, AlerisLife paid an aggregate cash dividend of $50,000 to its stockholders. Our pro rata share of this cash dividend was $17,000.
See Note 6 for further information regarding our relationships, agreements and transactions with AlerisLife (including Five Star) and Note 2 for further information regarding our investment in AlerisLife.
Our Manager, RMR. We havetwo agreements with RMR to provide management services to us: (1) a business management agreement, which relates to our business generally; and (2) a property management agreement, which relates to the property level operations of many of our properties, including our medical office and life science properties, and major renovation or repositioning activities at our senior living communities that we may request RMR to manage from time to time. See Note 7 for further information regarding our management agreements with RMR.
Our Joint Ventures. In connection with our entering into the LSMD JV in January 2022, we paid mortgage escrow amounts and closing costs that were payable by that joint venture. The remaining costs totaled $4,056 as of December 31, 2024 and are included in other assets, net, in our consolidated balance sheet. RMR provides management services to each of the Seaport JV and the LSMD JV. See Note 7 for further information regarding those management agreements with RMR.
Leases with RMR. We lease office space to RMR in certain of our properties for RMR's property management offices. We recognized rental income from RMR for leased office space of $460, $196 and $303 for the years ended December 31, 2024, 2023 and 2022, respectively. Our office space leases with RMR are terminable by RMR if our management agreements with RMR are terminated.
Share Awards to RMR Employees. As described in Note 5, we award shares to our officers and other employees of RMR annually. Generally, one fifth of these awards vest on the award date and one fifth vests on each of the next four anniversaries of the award dates. In certain instances, we may accelerate the vesting of an award, such as in connection with the award holder's retirement as an officer of us or an officer or employee of RMR. These awards to RMR employees are in addition to the share awards to our Managing Trustees, as Trustee compensation, and the fees we paid to RMR. See Note 5 for information regarding our share awards and activity as well as certain share purchases we made in connection with share award recipients satisfying tax withholding obligation on vesting share awards.
Note 9. Indebtedness
At December 31, 2024 and 2023, our outstanding indebtedness consisted of the following:
Senior Unsecured Notes:
| Principal Balance as ofDecember 31, | ||||
|---|---|---|---|---|
| Coupon Rate | Maturity | 2024 | 2023 | |
| Senior unsecured notes (1) | 9.750% | June 2025 | $380,000 | $500,000 |
| Senior unsecured notes | 4.750% | February 2028 | 500,000 | 500,000 |
| Senior unsecured notes (1) | 4.375% | March 2031 | 500,000 | 500,000 |
| Senior unsecured notes | 5.625% | August 2042 | 350,000 | 350,000 |
| Senior unsecured notes | 6.250% | February 2046 | 250,000 | 250,000 |
| Total | 1,980,000 | 2,100,000 | ||
| Unamortized discount | (2,639) | (3,483) | ||
| Unamortized debt issuance costs | (20,042) | (23,899) | ||
| Senior unsecured notes, net | $1,957,319 | $2,072,618 | ||
(1)These notes are fully and unconditionally guaranteed, on a joint, several and unsecured basis, by all of our subsidiaries except certain excluded subsidiaries. The notes and related guarantees are effectively subordinated to all of our and the subsidiary guarantors' secured indebtedness, respectively, to the extent of the value of the applicable collateral, and are structurally subordinated to all indebtedness and other liabilities and any preferred equity of any of our subsidiaries that do not guarantee the notes.
Secured and Other Debt:
| Number ofProperties Secured By · Principal Balance as ofDecember 31, (1) · Net Book Value of Collateral as of December 31, | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| At December 31, 2024 · At December 31, 2023 · 2024 · 2023 · InterestRate · Maturity · 2024 · 2023 | ||||||||||
| Senior secured notes (2)(3)(4) | 95 | 95 | $940,534 | $940,534 | 0.00% | January 2026 | $1,064,171 | $1,075,889 | ||
| Mortgage note | 8 | — | 120,000 | — | 6.86% | June 2034 | 191,186 | — | ||
| Mortgage note | 1 | 1 | 7,464 | 9,109 | 6.44% | July 2043 | 13,097 | 13,589 | ||
| Finance Leases | 2 | 2 | 2,338 | 3,911 | 7.70% | April 2026 | 21,606 | 22,765 | ||
| Total | 106 | 98 | 1,070,336 | 953,554 | $1,290,060 | $1,112,243 | ||||
| Unamortized discount (3) | (101,035) | (187,813) | ||||||||
| Unamortized debt issuance costs | (15,716) | (21,510) | ||||||||
| Total secured and other debt, net | $953,585 | $744,231 | ||||||||
(1)The principal balances are the amounts stated in the contracts. In accordance with GAAP, our carrying values and recorded interest expense may be different because of market conditions at the time we assumed certain of these debts.
(2)These notes are fully and unconditionally guaranteed, on a joint, several and senior secured basis by certain of our subsidiaries that own 95 properties, or the Collateral Guarantors, and on a joint, several and unsecured basis, by all our subsidiaries other than the Collateral Guarantors and certain excluded subsidiaries. These notes and the guarantees provided by the Collateral Guarantors are secured by a first priority lien on and security interest in each of the collateral properties and 100% of the equity interests in each of the Collateral Guarantors. The guarantees provided by all our subsidiaries other than the Collateral Guarantors and certain excluded subsidiaries are effectively subordinated to all of the subsidiary guarantors' secured indebtedness to the extent of the value of the applicable collateral, and the notes and related guarantees are structurally subordinated to all indebtedness and other liabilities and any preferred equity of any of our subsidiaries that do not guarantee the notes.
(3)These notes require no cash interest to accrue prior to maturity and will accrete at a rate of 11.25% per annum compounded semiannually on January 15 and July 15 of each year, such that the accreted value will equal the principal amount at maturity. The unamortized discount is related to these notes.
(4)We have a one-time option to extend the maturity date of these notes byone year, to January 15, 2027, subject to satisfaction of certain conditions and payment of an extension fee. If we exercise this option, interest payments will be due semiannually during the extension period at an initial interest rate of 11.25% with increases of 50 basis points every 90 days these notes remain outstanding.
Until its repayment in full and termination on December 21, 2023, we had a $450,000 credit facility that was fully drawn. The weighted average annual interest rate for borrowings under our former credit facility was 7.9% and 4.5% for the years ended December 31, 2023 and 2022, respectively.
As of December 31, 2024, all $940,534 of our senior secured notes due 2026 are fully and unconditionally guaranteed, on a joint, several and senior secured basis by the Collateral Guarantors and on a joint, several and unsecured basis, by all our subsidiaries other than the Collateral Guarantors and certain excluded subsidiaries, and all $380,000 of our 9.75% senior notes due 2025 and all $500,000 of our 4.375% senior notes due 2031 were fully and unconditionally guaranteed, on a joint, several and unsecured basis, by all of our subsidiaries except certain excluded subsidiaries. The notes and related guarantees (other than our senior secured notes and the guarantees provided by the Collateral Guarantors) are effectively subordinated to all of our and the subsidiary guarantors' secured indebtedness, respectively, to the extent of the value of the applicable collateral, and the notes and related guarantees are structurally subordinated to all indebtedness and other liabilities and any preferred equity of any of our subsidiaries that do not guarantee the notes. Our remaining $1,100,000 of senior unsecured notes do not have the benefit of any guarantees as of December 31, 2024. In January 2025, we sold three properties that secure these senior secured notes for a sales price of $159,025, excluding closing costs. As of February 24, 2025, we are under agreements to sell 19 additional properties that secure these senior secured notes for an expected aggregate sales price of $142,100, excluding closing costs. The net proceeds from these sales will be used to partially redeem these senior secured notes due 2026.
Our senior secured notes due 2026 and the guarantees provided by the Collateral Guarantors are secured by a first priority lien and security interest in each of the collateral properties and 100% of the equity interests in each of the Collateral Guarantors. No cash interest will accrue on these notes prior to maturity. The accreted value of these notes will increase at a rate of 11.25% per annum compounded semiannually on January 15 and July 15 of each year, such that the accreted value will equal the principal amount at maturity. During the years ended December 31, 2024 and 2023, we recognized discount accretion of $86,778 and $2,720, respectively, for our senior secured notes due 2026 in interest expense in our consolidated statements of comprehensive income (loss).
We have a significant number of unencumbered properties in our SHOP segment. As of December 31, 2024, our unencumbered gross book value of real estate assets was $5,016,878. As of February 21, 2025, we have executed term sheets with various lenders for proceeds of approximately $276,000, and are in active negotiations with an additional lender for expected proceeds of $64,000, for loans that will be secured by certain of our unencumbered SHOP communities. We believe that with $144,584 of cash and cash equivalents as of December 31, 2024, the above referenced loan proceeds and proceeds from sales of certain unencumbered properties, we will satisfy the $380,000 outstanding principal amount of 9.75% senior unsecured notes due in June 2025, which is our next significant debt maturity.
The table below represents our indebtedness repayments, excluding scheduled payments on amortizing debt, for the years ended December 31, 2024, 2023 and 2022:
| Date · Debt Instrument · Secured Property Count · Interest Rate · Original Maturity Date · Outstanding Principal Balance · Repayment Amount · Remaining Principal Balance · Loss (gain) on Modification or Early Extinguishment of Debt | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Repayments during the year ended December 31, 2024: | ||||||||||
| November 2024 | Senior unsecured notes | — | 9.75% | June 2025 | $440,000 | $60,000 | $380,000 | $115 | ||
| June 2024 | Senior unsecured notes | — | 9.75% | June 2025 | $500,000 | 60,000 | $440,000 | 209 | ||
| Total | $120,000 | $324 | ||||||||
| Repayments during the year ended December 31, 2023: | ||||||||||
| December 2023 | Senior unsecured notes | — | 4.75% | May 2024 | $250,000 | $250,000 | $— | $1,079 | ||
| December 2023 | Secured credit facility (1) | 62 | 8.36% | January 2024 | $450,000 | 450,000 | $— | 314 | ||
| April 2023 | Mortgage note | 1 | 6.64% | June 2023 | $14,565 | 14,565 | $— | — | ||
| February 2023 | Secured credit facility (1) | 61 | 7.05% | January 2024 | $586,373 | 136,373 | $450,000 | 1,075 | ||
| January 2023 | Secured credit facility (1) | 61 | 6.88% | January 2024 | $700,000 | 113,627 | $586,373 | — | ||
| Total | $964,565 | $2,468 | ||||||||
| Repayments during the year ended December 31, 2022: | ||||||||||
| October 2022 | Mortgage note | 1 | 4.85% | October 2022 | $10,287 | $10,287 | $— | $— | ||
| July 2022 | Mortgage note | 2 | 5.75% | October 2022 | $15,273 | 15,273 | $— | — | ||
| June 2022 | Senior unsecured notes | — | 9.75% | June 2025 | $1,000,000 | 500,000 | $500,000 | 29,576 | ||
| April 2022 | Mortgage note | 1 | 6.28% | July 2022 | $10,934 | 10,934 | $— | (16) | ||
| February 2022 | Secured credit facility (1) | 61 | 2.85% | January 2024 | $800,000 | 100,000 | $700,000 | 483 | ||
| Total | $636,494 | $30,043 | ||||||||
(1)The interest rate presented for the secured credit facility reflects the interest rate at the time repayment was made.
In December 2023, we issued $940,534 in aggregate principal amount at maturity of our senior secured notes due 2026 in a private offering, raising net proceeds of $730,359, after deducting initial purchaser discounts and estimated offering costs.
In May 2024, we executed a $120,000 fixed rate, interest only mortgage loan secured byeight medical office and life science properties. This mortgage loan matures in June 2034 and requires that interest be paid at an annual rate of 6.864%.
Interest on our senior unsecured notes are payable either semi-annually or quarterly in arrears; however, no principal repayments are due until maturity. No interest is payable on our senior secured notes with the full principal amount due at maturity. Our mortgage note due June 2034 requires monthly interest payments and no principal payment is due until maturity, and our mortgage note due July 2043 requires monthly principal and interest payments. Payments under our finance leases are due monthly. We include amortization of finance lease assets in depreciation and amortization expense.
Our senior notes indentures and their supplements provide for acceleration of payment of all amounts outstanding upon the occurrence and continuation of certain events of default. Our senior notes indentures and their supplements also contain covenants that restrict our ability to incur debts, including debts secured by mortgages on our properties, in excess of calculated amounts and require us to maintain various financial ratios.
Required principal payments on our outstanding debt as of December 31, 2024, were as follows:
| Year | Principal Payment |
|---|---|
| 2025 | $381,940 |
| 2026 (1) | 941,379 |
| 2027 | 245 |
| 2028 | 500,261 |
| 2029 | 278 |
| Thereafter | 1,226,233 |
| Total | $3,050,336 |
(1)We have aone year extension option for the maturity date of our $940,534 senior secured notes.
Note 10. Fair Value of Assets and Liabilities
The following table presents certain of our assets that are measured at fair value at December 31, 2024 and 2023, categorized by the level of inputs as defined in the fair value hierarchy under GAAP, used in the valuation of each asset.
| As of December 31, 2024 | As of December 31, 2023 | |||
|---|---|---|---|---|
| Description | Carrying Value | Estimated Fair Value | Carrying Value | Estimated Fair Value |
| Recurring Fair Value Measurements Assets: | ||||
| Investment in unconsolidated joint venture (Level 3) (1) | $81,949 | $81,949 | $85,699 | $85,699 |
| Investment in unconsolidated joint venture (Level 3) (2) | $44,910 | $44,910 | $44,217 | $44,217 |
| Non-Recurring Fair Value Measurements Assets: | ||||
| Real estate properties held for sale (Level 2) (3) | $24,074 | $24,074 | $— | $— |
(1)The 10% equity interest we own in the Seaport JV is included in investments in unconsolidated joint ventures in our consolidated balance sheet, and is reported at fair value, which is based on significant unobservable inputs (Level 3 inputs). The significant unobservable inputs used in the fair value analysis are a discount rate of 7.00%, an exit capitalization rate of 6.00%, a holding period of 10 years and market rents. The assumptions made in the fair value analysis are based on the location, type and nature of the property, and current and anticipated market conditions. See Note 3 for further information regarding this joint venture.
(2)The 20% equity interest we own in the LSMD JV is included in investments in unconsolidated joint ventures in our consolidated balance sheet, and is reported at fair value, which is based on significant unobservable inputs (Level 3 inputs). The significant unobservable inputs used in the fair value analysis are discount rates of between 6.25% and 7.75%, exit capitalization rates of between 5.00% and 7.00%, holding periods of 10 years and market rents. The assumptions we made in the fair value analysis are based on the location, type and nature of each property, and current and anticipated market conditions. See Note 3 for further information regarding this joint venture.
(3)We have assets in our consolidated balance sheets that are measured at fair value on a non-recurring basis. During the year ended December 31, 2024, we recorded impairment charges of $29,016 to reduce the carrying value oftwo medical office and life science properties that are classified as held for sale to their estimated aggregate sales price, less estimated costs to sell, of $24,074 under agreements or letters of intent to sell that, as of December 31, 2024, we had entered into with third parties. See Note 3 for further information about impairment charges and the properties we have classified as held for sale.
In addition to the assets described in the table above, our financial instruments at December 31, 2024 and December 31, 2023 included cash and cash equivalents, restricted cash, certain other assets, senior unsecured notes, senior secured notes, secured debt and finance leases and certain other unsecured obligations and liabilities. The fair values of these financial instruments approximated their carrying values in our consolidated financial statements as of such dates, except as follows:
| As of December 31, 2024 | As of December 31, 2023 | |||
|---|---|---|---|---|
| Description | Carrying Value (1) | Estimated Fair Value | Carrying Value (1) | Estimated Fair Value |
| Senior unsecured notes, 9.750% coupon rate, due 2025 | $379,392 | $379,970 | $497,454 | $490,750 |
| Senior secured notes, zero coupon rate, due 2026 | 826,974 | 885,108 | 731,211 | 771,981 |
| Senior unsecured notes, 4.750% coupon rate, due 2028 | 496,018 | 429,170 | 494,746 | 384,110 |
| Senior unsecured notes, 4.375% coupon rate, due 2031 | 494,702 | 368,240 | 493,845 | 375,000 |
| Senior unsecured notes, 5.625% coupon rate, due 2042 | 343,302 | 218,260 | 342,946 | 211,400 |
| Senior unsecured notes, 6.250% coupon rate, due 2046 | 243,905 | 157,700 | 243,627 | 154,000 |
| Secured debts and finance leases | 126,611 | 126,001 | 13,020 | 12,284 |
| $2,910,904 | $2,564,449 | $2,816,849 | $2,399,525 | |
(1)Includes unamortized net premiums, discounts and debt issuance costs, if any.
We estimated the fair values of ourtwo issuances of senior unsecured notes due 2042 and 2046 based on the closing price on Nasdaq (Level 1 inputs as defined in the fair value hierarchy under GAAP) as of December 31, 2024 and 2023. We estimated the fair values of ourthree issuances of senior unsecured notes due 2025, 2028 and 2031 and our issuance of senior secured notes due 2026 using an average of the bid and ask price on Nasdaq on or about December 31, 2024 and 2023 (Level 2 inputs as defined in the fair value hierarchy under GAAP). We estimated the fair values of our secured debts by using discounted cash flows analyses and currently prevailing market terms as of the measurement date (Level 3 inputs as defined in the fair value hierarchy under GAAP). Because Level 3 inputs are unobservable, our estimated fair values may differ materially from the actual fair values.
Note 11. Segment Reporting
Our operating segments are based on our internal reporting structure and property type and are aligned with how our CODM reviews the operating results to allocate resources and assess segment performance. The CODM is our President and Chief Executive Officer. Ourtwo reportable segments are Medical Office and Life Science Portfolio and SHOP. Our Medical Office and Life Science Portfolio segment primarily consists of medical office properties leased to medical providers and other medical related businesses, as well as life science properties primarily leased to biotech laboratories and other similar tenants. Our SHOP segment consists of managed senior living communities that provide short term and long term residential living and, in some instances, care and other services for residents where we pay fees to managers to operate the communities on our behalf. The significant expense categories and amounts presented below align with the segment-level information that is regularly provided to our CODM. The CODM reviews operating and financial results, including net income (loss) and its components, to assess performance, allocate resources and guide strategic decisions. The accounting policies of our reportable segments are the same as those described in Note 2. The tables below present information about our segments.
| Medical Office and Life Science Portfolio · SHOP · Total | ||||
|---|---|---|---|---|
| Revenues: | ||||
| Rental income | $213,320 | $— | $213,320 | |
| Residents fees and services | — | 1,244,389 | 1,244,389 | |
| Total segment revenues | 213,320 | 1,244,389 | 1,457,709 | |
| Reconciliation of revenue: | ||||
| Other revenue (1) | 37,718 | |||
| Total revenues | 1,495,427 | |||
| Less: | ||||
| Senior living labor and benefits | — | 630,998 | 630,998 | |
| Dietary | — | 85,620 | 85,620 | |
| Utilities | 13,687 | 70,616 | 84,303 | |
| Real estate taxes | 28,483 | 43,624 | 72,107 | |
| Insurance | 3,000 | 41,066 | 44,066 | |
| Other operating expenses (2) | 52,467 | 266,405 | 318,872 | |
| Interest expense | 5,743 | 229 | 5,972 | |
| Depreciation and amortization | 79,386 | 195,638 | 275,024 | |
| Other segment items (3) | 97,222 | — | 97,222 | |
| Segment loss | (66,668) | (89,807) | (156,475) | |
| Reconciliation of segment loss: | ||||
| Other income (1) | 27,209 | |||
| General and administrative | (26,518) | |||
| Acquisition and certain other transaction related costs | (2,510) | |||
| Interest and other income | 8,950 | |||
| Interest expense | (229,267) | |||
| Loss on modification or early extinguishment of debt | (324) | |||
| Income tax expense | (467) | |||
| Equity in net earnings of an investee | 9,147 | |||
| Net loss | $(370,255) | |||
(1)Revenue and net income from our triple net leased senior living communities and wellness centers that are leased to third party operators, which we do not consider to be sufficiently material to constitute a separate reportable segment.
(2)Other operating expenses for each reportable segment include expenses such as management fees, repairs and maintenance, cleaning and other costs incurred in connection with the operation of our properties.
(3)Other segment items for each reportable segment include impairment of assets, gain (loss) on sale of properties, gain (loss) on modification or early extinguishment of debt, equity in net earnings (losses) of investees and interest and other income, as applicable.
| Medical Office and Life Science Portfolio · SHOP · Total | ||||
|---|---|---|---|---|
| Revenues: | ||||
| Rental income | $220,530 | $— | $220,530 | |
| Residents fees and services | — | 1,151,908 | 1,151,908 | |
| Total segment revenues | 220,530 | 1,151,908 | 1,372,438 | |
| Reconciliation of revenue: | ||||
| Other revenue (1) | 37,870 | |||
| Total revenues | 1,410,308 | |||
| Less: | ||||
| Senior living labor and benefits | — | 603,711 | 603,711 | |
| Dietary | — | 78,508 | 78,508 | |
| Utilities | 13,918 | 69,280 | 83,198 | |
| Real estate taxes | 29,445 | 44,476 | 73,921 | |
| Insurance | 2,854 | 39,572 | 42,426 | |
| Other operating expenses (2) | 51,747 | 239,544 | 291,291 | |
| Interest expense | 449 | 551 | 1,000 | |
| Depreciation and amortization | 98,205 | 175,926 | 274,131 | |
| Other segment items (3) | 36,095 | (40) | 36,055 | |
| Segment loss | (12,183) | (99,620) | (111,803) | |
| Reconciliation of segment loss: | ||||
| Other income (1) | 26,822 | |||
| General and administrative | (26,131) | |||
| Acquisition and certain other transaction related costs | (10,853) | |||
| Gains on equity securities, net | 8,126 | |||
| Interest and other income | 13,955 | |||
| Interest expense | (190,775) | |||
| Loss on modification or early extinguishment of debt | (2,468) | |||
| Income tax expense | (445) | |||
| Net loss | $(293,572) | |||
(1)Revenue and net income from our triple net leased senior living communities and wellness centers that are leased to third party operators, which we do not consider to be sufficiently material to constitute a separate reportable segment.
(2)Other operating expenses for each reportable segment include expenses such as management fees, repairs and maintenance, cleaning and other costs incurred in connection with the operation of our properties.
(3)Other segment items for each reportable segment include impairment of assets, gain (loss) on sale of properties, gain (loss) on modification or early extinguishment of debt, equity in net earnings (losses) of investees and interest and other income, as applicable.
| Medical Office and Life Science Portfolio · SHOP · Total | ||||
|---|---|---|---|---|
| Revenues: | ||||
| Rental income | $222,390 | $— | $222,390 | |
| Residents fees and services | — | 1,022,826 | 1,022,826 | |
| Total segment revenues | 222,390 | 1,022,826 | 1,245,216 | |
| Reconciliation of revenue: | ||||
| Other revenue (1) | 38,350 | |||
| Total revenues | 1,283,566 | |||
| Less: | ||||
| Senior living labor and benefits | — | 566,384 | 566,384 | |
| Dietary | — | 69,455 | 69,455 | |
| Utilities | 13,555 | 66,470 | 80,025 | |
| Real estate taxes | 29,037 | 44,436 | 73,473 | |
| Insurance | 2,514 | 36,718 | 39,232 | |
| Other operating expenses (2) | 49,193 | 230,637 | 279,830 | |
| Interest expense | 913 | 1,534 | 2,447 | |
| Depreciation and amortization | 76,007 | 151,930 | 227,937 | |
| Other segment items (3) | (327,111) | (5,149) | (332,260) | |
| Segment income (loss) | 378,282 | (139,589) | 238,693 | |
| Reconciliation of segment income (loss): | ||||
| Other income (1) | 26,336 | |||
| General and administrative | (26,435) | |||
| Acquisition and certain other transaction related costs | (2,605) | |||
| Losses on equity securities, net | (25,660) | |||
| Interest and other income | 11,602 | |||
| Interest expense | (206,936) | |||
| Loss on modification or early extinguishment of debt | (30,059) | |||
| Income tax expense | (710) | |||
| Net loss | $(15,774) | |||
(1)Revenue and net income from our triple net leased senior living communities and wellness centers that are leased to third party operators, which we do not consider to be sufficiently material to constitute a separate reportable segment.
(2)Other operating expenses for each reportable segment include expenses such as management fees, repairs and maintenance, cleaning and other costs incurred in connection with the operation of our properties.
(3)Other segment items for each reportable segment include impairment of assets, gain (loss) on sale of properties, gain (loss) on modification or early extinguishment of debt, equity in net earnings (losses) of investees and interest and other income, as applicable.
| As of December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Assets (1) | |||
| Medical Office and Life Science Portfolio | $1,688,034 | $1,866,422 | $1,967,244 |
| SHOP | 3,084,101 | 3,134,978 | 3,147,785 |
| All Other | 364,870 | 444,736 | 887,064 |
| Total assets | $5,137,005 | $5,446,136 | $6,002,093 |
(1)See Note 3 for further information regarding additions to long-lived assets.
Note 12. Income Taxes
Our provision for income taxes consists of the following:
| For the Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Current: | |||
| Federal | $— | $(168) | $— |
| State | 467 | 613 | 710 |
| 467 | 445 | 710 | |
| Deferred: | |||
| Federal | — | — | — |
| State | — | — | — |
| — | — | — | |
| Income tax provision | $467 | $445 | $710 |
A reconciliation of our effective tax rate and the U.S. federal statutory income tax rate is as follows:
| For the Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Taxes at statutory U.S. federal income tax rate | 21.0% | 21.0% | 21.0% |
| Nontaxable income | (21.0)% | (21.0)% | (21.0)% |
| Federal excise tax | —% | 0.1% | —% |
| State and local income taxes, net of federal tax benefit | (0.1)% | (0.2)% | (4.5)% |
| Effective tax rate | (0.1)% | (0.1)% | (4.5)% |
Deferred income tax balances reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities in our consolidated balance sheets and the amounts used for income tax purposes and are stated at enacted tax rates expected to be in effect when taxes are actually paid or recovered. Significant components of our deferred tax assets and liabilities were as follows:
| For the Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Deferred tax assets: | ||
| Deferred income | $2,388 | $1,849 |
| Fair market value adjustment | (1,862) | — |
| Other | 1,225 | 1,196 |
| Tax loss carryforwards | 102,940 | 83,707 |
| 104,691 | 86,752 | |
| Valuation allowance | (104,691) | (86,752) |
| — | — | |
| Net deferred income taxes | $— | $— |
Because of our TRSs' history of losses, we are not able to conclude that it is more likely than not we will realize the future benefit of our deferred tax assets; thus we have provided a 100% valuation allowance as of December 31, 2024 and 2023. If and when we believe it is more likely than not that we will recover our deferred tax assets, we will reverse the valuation allowance as an income tax benefit in our consolidated statements of comprehensive income (loss). As of December 31, 2024, our consolidated TRSs had net operating loss carry forwards for federal income tax purposes of approximately $393,715, which do not expire. As of December 31, 2024, we, excluding our subsidiaries, had net operating loss carry forwards for federal income tax purposes of approximately $615,645, which do not expire. In the normal course of business, income tax authorities in various income tax jurisdictions conduct routine audits of our income tax returns filed in prior years. Income tax years subsequent to 2020 may be open to examination in some of the income tax jurisdictions in which we operate.
Note 13. Weighted Average Common Shares
We calculate basic earnings per common share using the two class method. We calculate diluted earnings per share using the more dilutive of the two class method or the treasury stock method. Unvested share awards and other potentially dilutive common shares, together with the related impact on earnings, are considered when calculating diluted earnings per share.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.